Getinge Group: Correction: Getinge Announces Preliminary Results for Third Quarter 2013 Business Wire GETINGE, Sweden -- October 8, 2013 Regulatory News: Getinge (STO:GETIB): Getinge’s consolidated profit before tax for the third quarter 2013 is expected to amount to 560-570 MSEK, which materially deviates from the expectations indicated by the market consensus estimate. The weaker earnings statement is primarily attributable to the following factors: - unfavorable product mix within the Critical Care division - time delay in cost synergies related to the TSS acquisition - the US Medical Device Tax and negative exchange-rate effects For the full year, the organic volume growth is still expected to exceed last year and amount to approximately 3-4 %. Profit before tax for the full year is estimated to total at 3000 – 3200 MSEK including restructuring expenses and other nonrecurring expenses. This announcement will be followed by a conference call at 10.00 AM CET today, hosted by Johan Malmquist, CEO Getinge Group and Ulf Grunander, CFO Getinge Group. Getinge will issue its full Q3 report for 2013 on October 15th at 1:00 PM CET. Conference Call To participate, please call: Sweden: +46 (0)8 5065 3938 UK: +44 (0)20 3427 1905 Passcode: 7592961 Agenda 09.45 Call the conference number 10.00 Introduction 10.10 Q&A 11.00 End of conference A recorded version of the conference will be accessible for five working days at the following number: Sweden: +46 (0)8 5051 3897 UK: +44 (0)20 3427 0598 US: +1347366 9565 Passcode: 7592961 GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care. The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was brought to you by Cision http://news.cision.com Contact: Getinge Group Johan Malmquist, CEO Phone: +46 10 335 55 33 Email: firstname.lastname@example.org or Ulf Grunander, CFO Phone: +46 10 335 55 80 Email: email@example.com
Getinge Group: Correction: Getinge Announces Preliminary Results for Third Quarter 2013
Press spacebar to pause and continue. Press esc to stop.